Anxiety disorders in patients after stroke: clinical significance, detection and current approach to pharmacotherapy

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Jul 31, 2017
DOI: https://doi.org/10.30841/2307-5112.3(71).2017.116765
Keywords:
stroke, late neurological complications of stroke, anxiety disorders, antipsychotics, sulpiride,

##plugins.themes.bootstrap3.article.main##

Ю. О. Матяш
Медицинский центр «Универсальная клиника «Оберіг», Ukraine
Ю. В. Фломін
Медицинский центр «Универсальная клиника «Оберіг», Ukraine

Abstract

In the review, we discuss prevalence of anxiety disorders, most frequent clinical syndromes, importance of their recognition in poststroke patients and up to date principles of pharmacological therapy for anxiety disorders. Role of drugs classified as ‘minor’ antipsychotics, such as sulpiride, in various anxiety disorders is reviewed.

##plugins.themes.bootstrap3.article.details##

How to Cite
Матяш, Ю. О., & Фломін, Ю. В. (2017). Anxiety disorders in patients after stroke: clinical significance, detection and current approach to pharmacotherapy. Family Medicine, (3(71), 120–125. https://doi.org/10.30841/2307-5112.3(71).2017.116765
Issue
No. 3(71) (2017)
Section
Neurology
Copyright (c) 2020 Ю. О. Матяш, Ю. В. Фломін

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

Ю. О. Матяш, Медицинский центр «Универсальная клиника «Оберіг»

Y.A. Matyash

Ю. В. Фломін, Медицинский центр «Универсальная клиника «Оберіг»

Y.V. Flomin

References

Бурчинський С.Г. Нові аспекти фармакотерапії психосоматичної патології // Ліки. – 2004. – No 5–6. – С. 28–32; Карвасарский Б.Д. Неврозы. – М.: Медицина, 1990. – 573 с.

Вельтищев Д.Ю. Многоликий Эглонил // РМЖ. – 2001. – No 25. – С. 1197.

Воробьева О.В. Тревожные расстройства в неврологической практике // РМЖ. – 2007. – No 24. – С. 1820.

Международная статистическая классификации болезней и проблем, связанных со здоровьем, 10-го пересмотра.

Приходько В.Ю., Микропуло И.Р., Кононенко Е.А., Морева Д.Ю. Психоэмоциональные расстройства и кардиоваскулярный риск // Журнал «Нейро News: психоневрология и нейропсихиатрия», 2(47) 2013.

Романенко В.И., Романенко И.В., Романенко И.Ю. Особенности психо-вегетативных нарушений при хроническом болевом синдроме // Український журнал болю No 1 (5), 2016.

Халік О.О. Тривожність як чинник дезадаптації практичних психологів початківців: Автореф. дис. ... канд. психолог. наук: спец.: 19.00.07/ Нац. пед. ун-т ім. М.П. Драгоманова. – К., 2010. – 16 с.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing, 2013.

BermanRM, FavaM, ThaseMEetal. Aripiprazole augmentation in major depressive disorder: a double blind, placebo controlled study in patients with inadequate response to antidepressants. CNSSpectr 2009; 14: 197–206.

Brown RG, Landau S, Hindle JV, Playfer J, Samuel M, Wilson K Cetal. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2011; 82:803–9; Campbell Burton CA, Holmes J, Murray J, Gillespie D, Lightbody CE, Watkins CL et al. Interventions for treating anxiety after stroke. Cochrane Database Syst Rev 2011; (12):CD008860.

Bruce M, Scott N, Shine P, Lader M. Anxiogenic effects of caffeine in patients with anxiety disorders. // Arch Gen Psychiatry 1992;49:867–869.

Campbell Burton CA, Murray J, Holmes J, Astin F, Greenwood D, Knapp P. Frequency of anxiety after stroke: a systematic review and meta analysis of observational studies. Int J Stroke. 2013 Oct; 8(7):545 59; Schцttke H, Giabbiconi CM. Post stroke depression and post stroke anxiety: prevalence and predictors. Int Psychogeriatr. 2015 Nov; 27(11):1805 12; Cumming TB, Blomstrand C, Skoog I, Linden T. The High Prevalence of Anxiety Disorders After Stroke. Am J Geriatr Psychiatry. 2016 Feb;24(2):154–60.

Campbell Burton CA, Murray J, Holmes J, Astin F, Greenwood D, Knapp P. Frequency of anxiety after stroke: a systematic review and meta analysis of observational studies. Int J Stroke. 2013 Oct; 8(7):545 59; Cumming TB, Blomstrand C, Skoog I, Linden T. The High Prevalence of Anxiety Disorders After Stroke. Am J Geriatr Psychiatry. 2016 Feb; 24(2):154–60.

Comer JS, Mojtabai R, Olfson M. National trend sinthe antipsychotic treatment of psychiatric out patient swithanxiety disorders. AmJPsychiatry. 2011 Oct; 168(10):1057–65.

delaMora MP, Gallegos Cari A, Arizmendi Garcia Y, Marcellino D, Fuxe K. Role of dopamine receptor mechanism sintheamygdaloid modulation offear and anxiety: structural and functional analysis. ProgNeurobiol 2010; 90(2):198–216.

Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017.

Donnellan C, Hickey A, Hevey D, O’Neill D. Effect of mood symptoms on recovery one year after stroke. Int J Geriatr Psychiatry 2010; 25:1288–95; Martens EJ, de Jonge P, Na B, Cohen BE, Lett H,Whooley MA. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Gen Psychiatry 2010; 67:750–8.

European Guidelines on cardiovascular disease prevention in clinical practice, 2012.

FeiginVL, ForouzanfarMH, Krishna murthiR, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383: 245–54

Feigin VL, Krishnamurthi RV, Parmar P, Norrving B, Mensah GA, Bennett DA et al.; GBD 2013 Writing Group; GBD 2013 Stroke Panel Experts Group.Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990 2013: The GBD 2013 Study. Neuroepidemiology. 2015; 45(3): 161–76.

Feigin VL, Norrving B, George MG, Foltz JL, Roth GA, Mensah GA. Prevention of stroke: a strategic global imperative. Nat Rev Neurol. 2016 Sep;12(9):501 12; Hankey GJ. Stroke. Lancet. 2017 Feb 11; 389 (10069): 641–654.

Holt RL, Lydiard RB. Management of treatment resistant panic disorder. Psychiatry 2007; 4(10):48–59.

Katon W, Hollifield M, Chapman T et al. Infrequent panic attacks: psychiatric comorbidity, personal characterisitics and functional disability. // J Psych Research 1995; 29: 121–131.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive compulsive disorders. BMC Psychiatry. 2014; 14 Suppl 1:S1.

Kessler R, DuPont R, Berglund P, Wittchen H. Impairmentinpure and comorbid generalized anxiety disorder and major depression at 12 months intwonationalsurveys. Am J Psychiatry 1999; 156:1915–23; Kessler R. The epidemiology of pure and comorbid Generalized Anxiety Disorder: a review and evaluation of recent research. Acta Psychiatr Scand Suppl 2000; 406: 7–13; Ayerbe L, Ayis S, Wolfe CD, Rudd AG. Natural history, predictors and outcomes of depression after stroke: systematic review and meta analysis. Br J Psychiatry. 2013 Jan;202(1):14–21.

Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10:79–104.

Nunes EA, Freire RC, Dos Reis M, de Oliveira E Silva AC, Machado S, Crippa JA et al. Sulpiride and refractory panic disorder. Psychopharmacology (Berl). 2012 Sep; 223(2):247–9.

Pérez Piñar M, Ayerbe L, González E, Mathur R, Foguet Boreu Q, Ayis S. Anxiety disorders and risk of stroke: A systematic review and meta analysis. Eur Psychiatry. 2017 Mar; 41:102–108.

Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 1996; 168: 38–43.

Towfighi A, Ovbiagele B, ElHusseini N, Hackett ML, Jorge RE, Kissela BM; American Heart Association Stroke Council; Councilon Cardiovascular and Stroke Nursing; Councilon Quality of Careand Outcomes Research. Poststroke Depression: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Feb; 48(2):e30-e43.

Vil’yanov VB, Kremenitskaya SA, Solov’eva NV. The efficacy of sulpiride in patients with anxiety disorders depending on the serum serotonin concentrations [Article in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(10):62–5.

Western Australian Psychotropic Drugs Committee. Anxiety Disorders Drug Treatment Guidelines, 2008; www.jpshealthnet.org.

Wittchen H.U., Jacobi F., Rehm J. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010 // Eur Neuropsychopharmacol. – 2011. – P. 655–679.